Výsledky vyhledávání - "Jacqueline Aussie"

PCA3 Molecular Urine Test for Predicting Repeat Prostate Biopsy Outcome in Populations at Risk: Validation in the Placebo Arm of the Dutasteride REDUCE Trial

Autor: Sheila M.J. Aubin, Jennifer Reid, Jacqueline Aussie, Roger S. Rittmaster, Gerald L. Andriole, Mark J. Sarno, Harry G. Rittenhouse, Jack Groskopf, Amy Blase

Publikováno v: Journal of Urology. 184:1947-1952

We determined the performance of PCA3 alone and in the presence of other covariates as an indicator of contemporaneous and future prostate biopsy results in a population with previous negative biopsy and increased serum prostate specific antigen.Urin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e8c263888f0be61420f17daad304c06
https://doi.org/10.1016/j.juro.2010.06.098

Zobrazit plný text záznamu

PD19-11 INDIVIDUALIZED PROSTATE CANCER RISK ASSESSMENT BY SERUM PSA, URINE TMPRSS2:ERG AND URINE PCA3

Autor: John T. Wei, Scott A. Tomlins, Javed Siddiqui, Sarah Meyer, Jacqueline Aussie, Sheila M.J. Aubin, Arul M. Chinnaiyan, Jack Groskopf, Robert J. Lonigro, John Day, Petrea Hodge

Publikováno v: Journal of Urology. 191

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9904566cf36a1b3a456590cc3cb65033
https://doi.org/10.1016/j.juro.2014.02.1530

Zobrazit plný text záznamu

2129 URINARY PCA3 AND TMPRSS2:ERG HELP PREDICT BIOPSY OUTCOME PRIOR TO INITIAL PROSTATE BIOPSY USING A RISK GROUP ANALYSIS

Autor: Jack Groskopf, Petrea Hodge, Jacqueline Aussie, LeRoy Jones, Sarah Meyer, John Day, Daniel Saltzstein

Publikováno v: Journal of Urology. 189

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::11a8fa07894dc2a9bb46e972a7c5f573
https://doi.org/10.1016/j.juro.2013.02.2038

Zobrazit plný text záznamu

Prostate cancer gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE trial

Autor: Jennifer Reid, Amy Blase, Harry G. Rittenhouse, Jack Groskopf, Roger S. Rittmaster, Jacqueline Aussie, Sheila M.J. Aubin, Mark J. Sarno, Gerald L. Andriole

Publikováno v: Urology. 78(2)

To examine the ability of the urinary prostate cancer gene 3 (PCA3) assay to predict biopsy-detected cancers in men receiving dutasteride in the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study cohort.Urine and serum samples from 930

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59366fd3245a3213465fdba48f968489
https://pubmed.ncbi.nlm.nih.gov/21820580

Zobrazit plný text záznamu

2062 PCA3 PREDICTS PROSTATE BIOPSY OUTCOME IN MEN RECEIVING DUTASTERIDE: RESULTS FROM THE DUTASTERIDE REDUCE TRIAL

Autor: Gerald Andriole, Sheila Aubin, Jennifer Reid, Mark Sarno, Amy Blase, Jacqueline Aussie, Harry Rittenhouse, Roger Rittmaster, Jack Groskopf

Publikováno v: Journal of Urology. 183

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b93d721a2d1a1bd7293b6857356a90d4
https://doi.org/10.1016/j.juro.2010.02.2109

Zobrazit plný text záznamu

2119 VALIDATION OF THE PCA3 MOLECULAR URINE TEST FOR PREDICTING REPEAT PROSTATE BIOPSY OUTCOME IN THE PLACEBO ARM OF THE DUTASTERIDE REDUCE TRIAL

Autor: Leonard Marks, Sheila Aubin, Jennifer Reid, Mark Sarno, Amy Blase, Jacqueline Aussie, Harry Rittenhouse, Gerald Andriole, Roger Rittmaster, Jack Groskopf

Publikováno v: Journal of Urology. 183

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1af1c13ca6b0fdfa7784108f49ad21eb
https://doi.org/10.1016/j.juro.2010.02.2207

Zobrazit plný text záznamu

The role of imaging with (111)In-ibritumomab tiuxetan in the ibritumomab tiuxetan (zevalin) regimen: results from a Zevalin Imaging Registry

Autor: Peter S, Conti, Christine, White, Peter, Pieslor, Arturo, Molina, Jacqueline, Aussie, Paul, Foster

Publikováno v: Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 46(11)

The ibritumomab tiuxetan therapeutic regimen consists of a dose of rituximab, 250 mg/m(2), followed by (111)In-ibritumomab tiuxetan, for imaging, on day 1 and a dose of rituximab followed by (90)Y-ibritumomab tiuxetan, for therapy, on day 7, 8, or 9.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::13005dd70ade469ffd72c4a0a4b6620a
https://pubmed.ncbi.nlm.nih.gov/16269594

Zobrazit plný text záznamu

Incidence of Altered Biodistribution Detected by Indium 111 (111In) Imaging Prior to Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy: Results from a Zevalin Imaging Registry

Autor: Gene Menendez, Christine A. White, Peter S. Conti, Jacqueline Aussie, P. Foster, Thomas Ryskamp, V. Douglas Harrough, Dan Matso, Peter C. Pieslor

Publikováno v: Blood. 104:4570-4570

Background: The yttrium 90 (90Y) ibritumomab tiuxetan (ZevalinÒ) therapeutic regimen consists of rituximab 250 mg/m2 on day 1 and 8, followed by indium 111 (111In) ibritumomab tiuxetan for imaging on Day 1 and 90Y ibritumomab tiuxetan for therapy o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d54a84e0719db210a78b417e3bad4560
https://doi.org/10.1182/blood.v104.11.4570.4570

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání